Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: 2017

    Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers

    20170213 ISI-JX FPI EN final

    Published 13 February 2017
    Categorized as 2017, Pexa-Vec, Press release

    Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

    Gilda G. Hillman, et al. Journal for ImmunoTherapy of Cancer, January 2017 – Download the article Publication

    Published 20 January 2017
    Categorized as 2017, Publication Tagged Poster presentation, Therapeutic Vaccine

    Transgene Announces Financial Calendar for 2017

    20170105 financial calendar EN

    Published 5 January 2017
    Categorized as 2017, Press release

    TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.

    Roland Kratzer, et al. AASLD & Hepatology, October 2016 – DOI: 10.1002/hep.28800 Download the poster here Poster Presentation

    Published 14 November 2016
    Categorized as 2017, Publication, TG1050 Tagged Poster presentation, Therapeutic Vaccine

    Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

    Patricia Kleinpeter, et al. OncoImmunology, October 2016 – Download the article Publication

    Published 28 October 2016
    Categorized as 2017, Publication Tagged Poster presentation, Therapeutic Vaccine

    Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities

    Johann Foloppe, et al. 10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016 Download the poster here Poster Presentation Collaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France

    Published 5 October 2016
    Categorized as 2017, Publication Tagged Poster presentation, Therapeutic Vaccine

    Posts navigation

    Newer posts Page 1 … Page 5
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo